Revumenib (SNDX-5613) is a first-in-class, effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Revumenib (SNDX-5613) can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Molecular Weight:
630.82
Purity:
>99%
CAS Number:
[2169919-21-3]
Formula:
C32H47FN6O4S
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted